Cost of treatment and reduction achieved by chronic ulcer in diabetic patients - a comparison between hydrogel and human recombinant epidermal growth factor
The study provides results from a double-blind clinical trial of 25 patients with diabetic or venous chronic ulcers. To evaluate the assessing cost of outpatient treatment with two technologies: 2% carboxymethylcellulose hydrogel or human recombinant Epidermal Growth Factor carbogel. Patients were randomly allocated to two ulcer treatment groups, human recombinant Epidermal Growth Factor treated (intervention group = 14), and 2% carboxymethylcellulose hydrogel (control group = 11); both treated during 90 days.